항암제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Oncology Drugs Market size is expected to reach USD 706.41 Billion in 2034 from USD 260.54 Billion (2025) growing at a CAGR of 11.72% during 2026-2034.

The global oncology drugs market has experienced significant growth due to the increasing prevalence of cancer and advancements in medical research. Oncology drugs are used to treat various types of cancer by targeting cancer cells or slowing their growth. Pharmaceutical companies and research institutions continue to develop innovative therapies to improve survival rates and treatment outcomes for patients.

Several factors are driving the growth of the oncology drugs market. Rising global cancer cases and growing awareness about early diagnosis have increased demand for effective treatments. Advances in biotechnology, immunotherapy, and targeted therapies have expanded treatment options, allowing healthcare providers to personalize cancer care.

The future outlook for the oncology drugs market remains promising as research continues to produce new treatment approaches. Ongoing clinical trials and advances in precision medicine may further improve treatment effectiveness. As healthcare systems expand access to advanced cancer therapies, the oncology drugs market is expected to grow steadily.

MARKET SEGMENTATION

By Drug Class

• Cytotoxic Drugs
• Targeted Drugs
• Hormonal Drugs
• Others

By Therapy

• Chemotherapy
• Targeted Therapy
• Immunotherapy

By Indication

• Lung Cancer
• Stomach Cancer
• Colorectal Cancer
• Breast Cancer
• Prostate Cancer
• Others

By Dosage Form

• Solid
• Liquid
• Injectable

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

COMPANIES PROFILED

• F HoffmannLa Roche Ltd, AbbVie Inc, Novartis AG, Pfizer Inc, Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, Bayer AG, Merck Co Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLOGY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Class
• 4.2. Cytotoxic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Targeted Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Hormonal Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLOGY DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Therapy
• 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Indication
• 6.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLOGY DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Dosage Form
• 7.2. Solid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 8.1. Market Analysis, Insights and Forecast Distribution Channel
• 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ONCOLOGY DRUGS MARKET: BY REGION 2022-2034 (USD MN)

• 9.1. Regional Outlook
• 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.2.1 By Drug Class
  • 9.2.2 By Therapy
  • 9.2.3 By Indication
  • 9.2.4 By Dosage Form
  • 9.2.5 By Distribution Channel
  • 9.2.6 United States
  • 9.2.7 Canada
  • 9.2.8 Mexico
• 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.3.1 By Drug Class
  • 9.3.2 By Therapy
  • 9.3.3 By Indication
  • 9.3.4 By Dosage Form
  • 9.3.5 By Distribution Channel
  • 9.3.6 United Kingdom
  • 9.3.7 France
  • 9.3.8 Germany
  • 9.3.9 Italy
  • 9.3.10 Russia
  • 9.3.11 Rest Of Europe
• 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.4.1 By Drug Class
  • 9.4.2 By Therapy
  • 9.4.3 By Indication
  • 9.4.4 By Dosage Form
  • 9.4.5 By Distribution Channel
  • 9.4.6 India
  • 9.4.7 Japan
  • 9.4.8 South Korea
  • 9.4.9 Australia
  • 9.4.10 South East Asia
  • 9.4.11 Rest Of Asia Pacific
• 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.5.1 By Drug Class
  • 9.5.2 By Therapy
  • 9.5.3 By Indication
  • 9.5.4 By Dosage Form
  • 9.5.5 By Distribution Channel
  • 9.5.6 Brazil
  • 9.5.7 Argentina
  • 9.5.8 Peru
  • 9.5.9 Chile
  • 9.5.10 Rest of Latin America
• 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 9.6.1 By Drug Class
  • 9.6.2 By Therapy
  • 9.6.3 By Indication
  • 9.6.4 By Dosage Form
  • 9.6.5 By Distribution Channel
  • 9.6.6 Saudi Arabia
  • 9.6.7 UAE
  • 9.6.8 Israel
  • 9.6.9 South Africa
  • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

• 10.1. Recent Developments
• 10.2. Company Categorization
• 10.3. Supply Chain & Channel Partners (based on availability)
• 10.4. Market Share & Positioning Analysis (based on availability)
• 10.5. Vendor Landscape (based on availability)
• 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ONCOLOGY DRUGS INDUSTRY

• 11.1. Top Companies Market Share Analysis
• 11.2. Company Profiles
  • 11.2.1 F. Hoffmann-La Roche Ltd
  • 11.2.2 AbbVie Inc
  • 11.2.3 Novartis AG
  • 11.2.4 Pfizer Inc
  • 11.2.5 Bristol Myers Squibb Company
  • 11.2.6 GlaxoSmithKline Plc
  • 11.2.7 Eli Lilly And Company
  • 11.2.8 AstraZeneca
  • 11.2.9 Sanofi
  • 11.2.10 Bayer AG
  • 11.2.11 Merck & Co. Inc